Bispecific T-cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single-chain variable fragments (scFv) ...
AM Huehls,TA Coupet,CL Sentman 摘要: Bispecific T-cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two ...
还存在模拟两种抗体的可变结构域的融合蛋白,这些较新格式的最远发展是双特异性T细胞接合者(bi-specific T-cell engagers,BiTEs) 二、Mechanism of action bsMab与其靶抗原的结合可导致多种效应。 该方法最广泛使用的应用是在癌症免疫疗法中,其中bsMab被工程化以同时结合细胞毒性细胞和靶标,如待破坏的肿瘤细胞。 Cat...
To date, >200 of these agents, the majority of which are bispecific immune cell engagers, are in either preclinical or clinical evaluation. In this Review, we discuss the role of bispecific antibodies in patients with cancer, including history and development, as well as innovative targeting ...
bispecific T cell engagers single-domain antibody CD1d Vγ9Vδ2-T cell type 1 NKT cell multiple myeloma acute myeloid leukemia chronic lymphocytic leukemia preclinical non-human primate Introduction T cell-engaging therapies are promising approaches in an expanding number of malignancies.1 Bispecific T...
Although there are several types of bsAbs, the most common are classified as trispecific antibodies and bispecific T-cell engagers (BiTEs).4 The only bsAb in the field of oncology that is FDA approved at the time of this publication is blinatumomab (Blincyto; Amgen). Blinatumomab is a BiTE ...
Recently, an approach using recombinant bispecific T-cell engagers (BiTEs), which consist of a tumor-targeting, single-chain antibody conjugated to a single-chain antibody directed against a T-cell activation ligand such as CD3, has arisen as a promising means for treating tumors. Human trials ...
Other examples are the constructs with their fragments connected by peptide chains, such as bispecific T cell engagers (BiTE) molecules, thereby circumventing random association of the chains (Mack, Riethmuller, & Kufer, 1995). 3.3. Rational design Like an antibody, a bsAb can be modified in ...
The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cells, exemplified by bispecific T cell engagers (BiTEs), have facilitated the development of tumor immunotherapy. Here we discussed the advances and challenges in BiTE therapy developed for the treatment of hematologic ...
Bispecific T-cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are cons... AM Huehls,TA Coupet,CL Sentman - 《Immunology & C...